Changing strategies in the management of asthma

REFERENCES

• Fleming DM, Crombie DL. Prevalence of asthma and hay fever in England and Wales. BMJ 1987; 294(6567): 279–83
   PubMedGoogle Scholar
• Benatar SR. Fatal asthma. N Engl J Med 1986: 314(7): 423–9
   PubMed Web of Science ®Google Scholar
• Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981–83: case-control study. Lancet 1989; 1(8644): 917–22
   PubMed Web of Science ®Google Scholar
• Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326(8): 501–6
   PubMed Web of Science ®Google Scholar
• Kerrebijn KF, van Essen-Zandvliet EE, Neijens HJ. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol 1987; 79(4): 653–9
   PubMed Web of Science ®Google Scholar
• van Schayck CP, Graafsma SJ, Visch MB, et al. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol 1990; 86(5): 793–800
   PubMed Web of Science ®Google Scholar
• Cheung D, Timmers MC, Zwinderman AH, et al. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992: 327(17): 1198–203
   PubMed Web of Science ®Google Scholar
• Barnes PJ. A new approach to the treatment of asthma. N EnglJ Med 1989: 321(22): 1517–27
   PubMed Web of Science ®Google Scholar
• Vathenen AS, Knox AJ, WIsniewski A, et al. Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis 1991; 143(6): 1317–21
   PubMedGoogle Scholar
• Toogood JH, Baskerville J, Jennings B, et al. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol 1989: 84(5 Pt l): 688–700
   PubMed Web of Science ®Google Scholar
• Moqbel R, Cromwell O, Walsh GM, et al. Effects of nedocromil sodium (Tilade) on the activation of human eosinophils and neutrophils and the release of histamine from mast cells. Allergy 1988; 43(4): 268–76
   PubMed Web of Science ®Google Scholar
• Thorel T, Joseph M, Tsicopoulos A, et al. Inhibition by nedocromil sodium of IgE-mediated activation of human mononuclear phagocytes and platelets in allergy. Int Arch Allergy Appi Immunol 1988; 85(2): 232–7
   PubMedGoogle Scholar
• Wells E, Jackson CG, Harper ST, et al. Characterization of primate bronchoalveolar mast cells. II. Inhibition of histamine, LTC4, and PGD2 release from primate bronchoalveolar mast cells and a comparison with rat peritoneal mast cells. J Immunol 1986: 137(12): 3941–5
   PubMed Web of Science ®Google Scholar
• Leung KB, Flint KC, Brostoff J, et al. A comparison of nedocromil sodium and sodium cromoglycate on human lung mast cells obtained by bronchoalveolar lavage and by dispersion of lung fragments. Eur J Respir Dis Suppl 1986: 147: 223–6
   PubMedGoogle Scholar
• Greif J, Fink G, Smorzik Y, et al. Nedocromil sodium and placebo in the treatment of bronchial asthma: a multicenter, doubleblind, parallel-group comparison. Chest 1989: 96(3): 583–8
   PubMed Web of Science ®Google Scholar
• Vandewalker ML, Kray KT, Weber RW, et al. Addition of terbutaline to optimal theophylline therapy: double blind crossover study in asthmatic patients. Chest 1986; 90(2): 198–203
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Greening AP, Neville L, et al. Single-dose slow-release aminophylline at night prevents nocturnal asthma. Lancet 1982; 1(8267): 299–301
   PubMed Web of Science ®Google Scholar
• Schild HO, Hawkins DF, Mongar JL, et al. Reactions of isolated human asthmatic lung and bronchial tissue to a specific antigen: histamine release and muscular contraction. Lancet 1951: 2: 376
   PubMedGoogle Scholar
• Phillips GD, Holgate ST. The effect of oral terfenadine atone and in combination with flurbiprofen on the bronchoconstrictor response to inhaled adenosine 5′-monophosphate in nonatopic asthma. Am Rev Respir Dis 1989: 139(2): 463–9
   PubMedGoogle Scholar
• Holgate ST, Emanuel MB, Howarth PH. Astemizole and other H1-antihistaminic drug treatment of asthma. J Allergy Clin Immunol 1985: 76(2 Pt 2): 375–80
   PubMed Web of Science ®Google Scholar
• Patel KR. The effect of calcium antagonist, nifedipine in exercise-induced asthma. Clin Allergy 1981: 11(5): 429–32
   PubMedGoogle Scholar
• Solway J, Fanta CH. Differential inhibition of bronchoconstriction by the calcium channel blockers, verapamil and nifedipine. Am Rev Respir Dis 1985; 132(3): 666–70
   PubMedGoogle Scholar
• Patel KR, Peers E. Felodipine, a new calcium antagonist, modifies exercise-induced asthma. Am Rev Respir Dis 1988; 138(l): 54–6
   PubMedGoogle Scholar
• Mullarkey MF, Blumenstein BA, Andrade WP, et al. Methotrexate in the treatment of corticosteroid-dependent asthma: a doubleblind crossover study. N Engl J Med 1988; 318(10): 603–7
   PubMed Web of Science ®Google Scholar
• Erzurum SC, Leff JA, Cochran JE, et al. Lack of benefit of methotrexate in severe, steroid-dependent asthma: a double-blind, placebo-controlled study. Ann Intern Med 1991: 114(5): 353–60
   PubMed Web of Science ®Google Scholar
• Evans TW, Chung KF, Rogers DF, et al. Effect of platelet-activating factor on airway vascular permeability: possible mechanisms. J Appl Physiol 1987; 63(2): 479–84
   PubMed Web of Science ®Google Scholar
• Chung KF, Barnes PJ. PAF antagonists: their potential therapeutic role in asthma. Drugs 1988; 35(2): 93–103
   PubMed Web of Science ®Google Scholar
• Koltai M, Hosfbrd D, Guinot P, et al. PAF. A review of its effects, antagonists and possible future clinical implications. II. Drugs 1991; 42(2): 174–204
   PubMed Web of Science ®Google Scholar
• Chung KF, Dent G, McCusker M, et al. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. Lancet 1987; 1(8527): 248–51
   PubMed Web of Science ®Google Scholar
• Casals-Stenzel J, Weber KH. Triazolodiazepines: dissociation of their PAF (platelet activating factor) antagonistic and CNS activity. Br J Pharmacol 1987; 90(l): 139–46
   PubMedGoogle Scholar
• Lewis RA, Austen KF. The biologically active leukotrienes: biosynthesis, metabolism, receptors, functions, and pharmacology. J Clin Invest 1984; 73(4): 889–97
   PubMed Web of Science ®Google Scholar
• Manning PJ, Watson RM, Margokkee DJ, et al. Inhibition of exercise-induced bronchoconstriction by MK-571: a potent leukotriene D4-receptor antagonist. N Engl J Med 1990: 323(25): 1736–9
   PubMed Web of Science ®Google Scholar
• Katayama S, Tsunoda H, Sakuma Y, et al. Effect of azelastine on the release and action of leukotriene C4 and D4. Int Arch Allergy Appi Immunol 1987; 83(3): 284–9
   PubMedGoogle Scholar
• Iwata M, Tano M, Sugiyama S, et al. Effect of azelastine, an antiasthmatic drug, on bronchial responsiveness in patients with bronchial asthma. Chest 1989; 95(6): 1231–4
   PubMed Web of Science ®Google Scholar
• Raffcrty P, Ng WH, Phillips G, et al. The inhibitory actions of azelastine hydrochloride on the early and late bronchoconstrictor responses to inhaled allergen in atopic asthma. J Allergy Clin Immunol 1989: 84(5 Pt l): 649–57
   PubMed Web of Science ®Google Scholar
• Knapp HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 1990; 323(25): 1745–8
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Dixon CM. The effect of inhaled vasoactive intestinal peptide on bronchial reactivity to histamine in humans. Am Rev Respir Dis 1984; 130(2): 162–6
   PubMedGoogle Scholar
• Ollerenshaw S, Jarvis D, Woolcock A, et al. Absence of immunoreactive vasoactive intestinal polypeptide in tissue from the lungs of patients with asthma. N Engl J Med 1989; 320(19): 1244–8
   PubMed Web of Science ®Google Scholar